Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Guo, Chengyue
Chen, Yanna
Zhu, Junzhe
Wang, Jiaxin
Xu, Ying
Luan, Hansen
and
Wang, Hao
2018.
Optimization of Extended-Release ZL-004 Nanosuspensions for In Vivo Pharmacokinetic Study to Enhance Low Solubility and Compliance.
Molecules,
Vol. 24,
Issue. 1,
p.
7.
Meyer, Jonathan M.
2018.
Converting oral to long-acting injectable antipsychotics: a guide for the perplexed– CORRIGENDUM.
CNS Spectrums,
Vol. 23,
Issue. 2,
p.
186.
Yan, Tingjian
Greene, Mallik
Chang, Eunice
Touya, Maëlys
and
Broder, Michael S
2018.
Impact of initiating long-acting injectable antipsychotics on hospitalization in patients with bipolar I disorder.
Journal of Comparative Effectiveness Research,
Vol. 7,
Issue. 11,
p.
1083.
Schoretsanitis, Georgios
Spina, Edoardo
Hiemke, Christoph
and
de Leon, Jose
2018.
A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting paliperidone.
Expert Review of Clinical Pharmacology,
Vol. 11,
Issue. 12,
p.
1237.
Correll, Christoph U.
Sliwa, Jennifer Kern
Najarian, Dean M.
and
Saklad, Stephen R.
2019.
Practical considerations for managing breakthrough psychosis and symptomatic worsening in patients with schizophrenia on long-acting injectable antipsychotics.
CNS Spectrums,
Vol. 24,
Issue. 4,
p.
354.
2019.
The Clozapine Handbook.
p.
78.
2019.
Therapie psychischer Erkrankungen.
p.
1.
2020.
Prescriber's Guide.
p.
313.
Stahl, Stephen M.
2020.
Prescriber's Guide.
2020.
Prescriber's Guide.
p.
347.
Meyer, Jonathan M.
2020.
Monitoring and improving antipsychotic adherence in outpatient forensic diversion programs.
CNS Spectrums,
Vol. 25,
Issue. 2,
p.
136.
Jain, Rakesh
Meyer, Jonathan
Wehr, Angela
Rege, Bhaskar
von Moltke, Lisa
and
Weiden, Peter J.
2020.
Size matters: the importance of particle size in a newly developed injectable formulation for the treatment of schizophrenia.
CNS Spectrums,
Vol. 25,
Issue. 3,
p.
323.
2021.
The Clinical Use of Antipsychotic Plasma Levels.
p.
114.
2021.
The Clinical Use of Antipsychotic Plasma Levels.
p.
318.
Zhu, Junli
Chen, Yun
Lu, Wei
Huang, Qingzhi
Li, Bin
Xu, Ying
Xi, Rui
and
Jin, Lefan
2021.
Attitudes and Willingness to Accept Long-Acting Injections for Patients With Schizophrenia in Beijing: A Cross-Sectional Investigation Based on Samples From the Communities.
Frontiers in Public Health,
Vol. 9,
Issue. ,
Kverno, Karan
and
Rozenberg, Ilya
2021.
Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia: Practical Considerations.
Journal of Psychosocial Nursing and Mental Health Services,
Vol. 59,
Issue. 7,
p.
7.
Landi, Giulia
Leuci, Emanuela
Quattrone, Emanuela
Azzali, Silvia
Pellegrini, Clara
Pellegrini, Pietro
and
Pelizza, Lorenzo
2021.
The ‘Parma‐Early Psychosis’ programme: Characterization of help‐seekers with first episode psychosis.
Early Intervention in Psychiatry,
Vol. 15,
Issue. 2,
p.
380.
Karava, Vasiliki
Siamidi, Aggeliki
Vlachou, Marilena
Christodoulou, Evi
Bikiaris, Nikolaos D.
Zamboulis, Alexandra
Kostoglou, Margaritis
Gounari, Eleni
and
Barmpalexis, Panagiotis
2021.
Poly(l-Lactic Acid)-co-poly(Butylene Adipate) New Block Copolymers for the Preparation of Drug-Loaded Long Acting Injectable Microparticles.
Pharmaceutics,
Vol. 13,
Issue. 7,
p.
930.
2021.
The Clinical Use of Antipsychotic Plasma Levels.
p.
157.
2021.
The Clinical Use of Antipsychotic Plasma Levels.
p.
190.